Patent intelligence · US
US 11077079
GHB formulation and method for its manufacture
GHB formulation and method for its manufacture
Patent details — US 11077079
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 3, 2021
- Expiration
- Jul 29, 2041
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Claims
- 18
- CPC classes
- A61K, A61K31/19, A61K31/785, A61K38/02
Quick answer
US 11077079 (GHB formulation and method for its manufacture) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals Ireland Limited
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/19, A61K31/785, A61K38/02, A61K9/10, A61K9/1635
More from Jazz Pharmaceuticals Ireland Limited
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 11077079?
US 11077079 (GHB formulation and method for its manufacture) is held by Jazz Pharmaceuticals Ireland Limited. Status: granted. Granted Aug 3, 2021. Expires Jul 29, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11077079?
Jazz Pharmaceuticals Ireland Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 11077079 expire?
Our index shows an expiration date of Jul 29, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.